论文部分内容阅读
目的为实现特异性细胞免疫抗癌治疗。自体固化瘤苗研究者，突破性将异体癌研制成功的异构性固化瘤苗，进行临床应用观察。方法瘤苗先经动物实验，药理和毒理试验，证明其制剂无毒付作用，和抗癌有效性后。我们院所合作，对１５６例多类（肺癌５３例，肝癌２２例，食道癌１４例，胃癌２５例，直肠癌１２例，乳腺癌３０例）癌，经手术切除主瘤但病理证实已有转移的中晚期癌症病人（自愿者）进行临床应用观察。结果获近期（三个月）临床抗癌有效率７５％（１１７／１５６），远期（三年）疗效６６．６％（１０３／１５６）。发现Ｔ淋巴细胞（ＣＴＬ）攻入癌细胞中，而使癌细胞凋亡。结论异构性固化瘤苗，能激活机体抗癌三分子复体免疫（ＳＴＶ－ＭＨＣ－ＴＣＲ）机制。实现了在人体内（ｉｎｖｉｒｏ途径）使癌细胞呈治疗性凋亡的特异性细胞免疫抗癌效果。
The purpose is to achieve specific cellular immune anti-cancer therapy. Researchers of autogenous solidified tumor vaccines have made breakthroughs in the development of heterogenous solidified tumor vaccines for the development of allogeneic cancers for clinical application. Methods Tumor vaccines were first subjected to animal experiments, pharmacological and toxicological tests, and proved to be nontoxic and effective after the anticancer effect. Our institute cooperated with 156 cases of multiple types (53 cases of lung cancer, 22 cases of liver cancer, 14 cases of esophageal cancer, 25 cases of gastric cancer, 12 cases of rectal cancer, and 30 cases of breast cancer). The main tumors were surgically resected and confirmed by pathology. Metastatic late-stage cancer patients (volunteers) were observed for clinical application. The results obtained in the recent (three months) clinical anti-cancer efficiency of 75% (117/156), long-term (three years) efficacy of 66.6% (103/156). It was found that T lymphocytes (CTL) attacked cancer cells and caused apoptosis of cancer cells. Conclusion Heterogeneous solidified tumor vaccine can activate the mechanism of anti-cancer three-complex immunity (STV-MHC-TCR). A specific cellular immune anti-cancer effect that enables therapeutic cells to undergo apoptosis in the human body (inviro pathway) is achieved.